卫光生物：向特定对象发行A股股票申请获受理

Core Viewpoint - The company has received a notification from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific stock issuance, which is subject to further approval and registration by regulatory authorities [1] Group 1 - The company announced that on October 10, 2025, it received a notice from the Shenzhen Stock Exchange about the acceptance of its application for a specific stock issuance [1] - The issuance of A-shares to specific investors requires approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1] - There is uncertainty regarding the approval process and the time required for it, and the company will fulfill its information disclosure obligations based on the progress [1]